Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiogenesis and tumor growth

Acta Biochimica et Biophysica Sinica

Volumn 38, Issue 7, 2006, Pages 514-521

  Cao, Jian Guo ^a,b   Peng, Shu Ping ^a   Sun, Li ^b   Li, Hui ^b   Wang, Li ^b   Deng, Han Wu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Angiogenesis inhibitor; Recombinant vascular basement membrane derived multifunctional peptide; Therapeutic action

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AUTOANTIGEN; COLLAGEN TYPE 4; HYBRID PROTEIN; IMMUNOGLOBULIN G; PEPTIDE; TYPE IV COLLAGEN ALPHA3 CHAIN;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BASEMENT MEMBRANE; CANCER TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; CYTOLOGY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENETICS; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; BASEMENT MEMBRANE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE IV; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

CRICETULUS GRISEUS; ESCHERICHIA COLI; PROKARYOTA;

EID: 33746216799     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2006.00183.x     Document Type: Article

References (40)

1. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972, 175: 409-416
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992, 267: 10931-10934
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79: 315-328
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277-285
6. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999, 285: 245-248
7. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000, 275: 21340-21348
8. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 1996, 8: 618-624
9. Prockop DJ, Kivirikko KI. Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995, 64: 403-434
10. Paulsson M. Basement membrane proteins: Structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992, 27: 93-127
11. Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: Structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993, 268: 26033-26036
12. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997, 272: 20395-203401
13. Pasco S, Han J, Gillery P, Bellon G, Maquart FX, Borel JP, Kefalides NA et al. A specific sequence of the noncollagenous domain of the α3 (IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 2000, 60: 467-473
14. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C et al. Extracellular matrix-derived peptide binds to α (v)β(3) integrin and inhibits angiogenesis. J Biol Chem 2001, 276: 31959-31968
15. Peng SP, Fang WY, Dai WJ, Zou XQ, Liu HY, Shi SH, Cao JG. Cloning expression and space conformation analysis of vascular basement membrane-derived multifunctional peptide. Chin J Cancer Biother 2003, 10: 185-189
16. Peng SP, Fang WY, Jiang RC, Zhou JG, Dong L, Cao JG. Prokaryotic expression of vascular basement membrane-derived multifunctional peptide and anti-tumor activity assay. Chinese Pharmacological Bulletin 2003, 19: 678-672
17. Cao JG, Tang XQ, Shi SH. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol 2004, 10: 3062-3064
18. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005, 26: 1009-1016
19. Heenen M, Laporte M. Molecular markers associated to prognosis of melanoma. Ann Dermatol Venereol 2003, 130: 1025-1031
20. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994, 127: 859-866
21. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000, 275: 1209-1215
22. Maxwell SA, Davis GE. Biological and molecular characterization of an ECV-304-derived cell line resistant to p53-mediated apoptosis. Apoptosis 2000, 5: 277-290
23. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-364
24. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997, 57: 3924-3928
25. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247: 77-79
26. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92: 391-400
27. Timpl R, Wiedemann H, van Delden V, Furthmayr H, Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem 1981, 120: 203-211
28. Turner N, Mason PJ, Brown R, Fox M, Povey S, Rees A, Pusey CD. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest 1992, 89: 592-601
29. Shahan TA, Ziaie Z, Pasco S, Fawzi A, Bellon G, Monboisse JC, Kefalides NA. Identification of CD47/integrin-associated protein and αvβ3 as two receptors for the α3(IV) chain of type IV collagen on tumor cells. Cancer Res 1999, 59: 4584-4590
30. Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, Monboisse JC. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 2004, 301: 251-265
31. Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, Maquart FX et al. The antitumor properties of the α3 (IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem 2004, 279: 2091-2100
32. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: Emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995, 11: 549-599
33. Mangano DT, Browner WS, Hollenberg M, Li J, Tateo IM. Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992, 268: 233-239
34. Maeshima Y, Colorado P C, and Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000, 275: 23745-23750
35. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE. Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995, 146: 1498-1507
36. Miyazaki YJ, Hamada J, Tada M, Furuuchi K, Takahashi Y, Kondo S, Katoh H et al. HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells. Oncogene 2002, 21: 798-808
37. Liapis H, Flath A, Kitazawa S. Integrin αvβ3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996, 5: 127-135
38. 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation. J Biol Chem 2000, 275: 32999-33007
39. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996, 65: 209-213
40. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295: 140-143